Humanigen Inc (HGENQ)

[cowtown jay]

"Very limited Supply of Lenz will only be 100k treatment courses in 2021."

I wonder if that is still accurate after the announcements in the last six weeks, or so, with Avid Bioservices and (Eversana?), to expand manufacturing services.

We announced a manufacturing agreement with Avid Bioservices on the 3rd. They are going to produce drug substance batches.

https://www.nasdaq.com/press-release/humanigen-and-avid-bioservices-enter-into-cgmp-manufacturing-agreement-for-covid-19-0

And I remember writing about another manufacturer who will provide fill finish services. It might have been Eversana, with whom we announced a partnership last month.

https://www.eversana.com/2021/01/10/humanigen-and-eversana-announce-partnership-to-support-the-launch-and-commercialization-of-lenzilumab-for-the-treatment-of-covid-19/

In addition, on the 22nd of last month, the company announced that BARDA had joined the agreement with Humanigen and CRADA, and that BARDA would allow us, "...to gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA)..."

https://www.biospace.com/article/releases/humanigen-announces-the-addition-of-barda-and-expansion-of-crada-with-the-u-s-government-to-develop-lenzilumab-for-covid-19/

I think Aji Pharma might have been the first manufacturer we partnered with, and that was a long time ago. I think they may have been involved with manufacturing the drugs we have had to supply for the BET trial, as well as our internal trial. They may have a significant inventory of lenz in anticipation of FDA approval. I think that was the goal, anyway. And we recently signed another agreement with them, too.

Then, too, we have agreements with a variety of others, as seen on slide 41 of the company's most recent presentation.

https://s27.q4cdn.com/938944131/files/doc_presentations/2021/HGEN-IR-deck-2.1.21.pdf

With all of the commercialization and distribution infrastructure we have put in place, along with CRADA, I think we should be capable of far exceeding the production of just 100,000 doses. I'd be surprised if we had just a, "Very limited Supply of Lenz..." in view of the recent events just discussed.

So, I wonder. What 2021 projections are the analysts using to estimate our revenue stream? I've said it before, the most disappointing thing to me, as a shareholder, are these analysts' estimates. Ridiculous.